

09/912,774

-2-

PC10915A

**Amendments to the Claims:**

1. (Currently Amended) A pharmaceutical composition in particulate form, suitable for oral administration, comprising: a core comprising a pharmaceutically acceptable seed; ~~a first layer containing~~ eletriptan hydrobromide dispersed on the seed; and a water insoluble layer ~~comprising~~ consisting essentially of a water permeable acrylic copolymer and optionally at least one of a plasticizer, an anti-tacking agent or a wetting agent, said composition being capable of achieving a sigmoidal pattern of controlled drug release.
2. (Canceled)
3. (Canceled)
4. (Canceled)
5. (Previously Presented) The composition of claim 1, wherein the acrylic copolymer comprises trimethylammoniummethyl-methacrylate groups.
6. (Original) The composition of claim 1, wherein the core has a diameter of from 0.2 to 2 mm.
7. (Original) The composition of claim 6, wherein the core has a diameter of from 0.5 to 1.4 mm.
8. (Original) The composition of claim 1, wherein the core contains from 10 to 90% W/W of eletriptan.
9. (Original) The composition of claim 8, wherein the core contains from 40 to 60% W/W of eletriptan.
10. (Original) The composition of claim 1, wherein the core includes eletriptan hydrobromide microcrystalline cellulose and lactose.
11. (Canceled)

09/912,774

-3-

PC10915A

12. (Canceled)

13. (Previously Presented) The composition of claim 1, wherein an additional protective layer is inserted between the core and the water-insoluble, permeable layer.

14. (Original) The composition of claim 13, wherein the additional protective layer includes a hydroxypropyl methylcellulose.

15. (Cancelled)

16. (Canceled)

17. (Previously Presented) The composition of claim 1, wherein the water-insoluble, permeable layer has a thickness of from 10 to 100 microns.

18. (Previously Presented) The composition of claim 17, wherein the water-insoluble, permeable layer has a thickness of from 40 to 80 microns.

19. (Previously Presented) The composition of claim 1, wherein the water-insoluble, permeable layer includes acrylic copolymer(s) containing trimethylammoniummethacrylate groups, talc and triethyl citrate.

20. (Previously Presented) A pharmaceutical formulation comprising a pharmaceutically acceptable component which is capable of delivering eletriptan, or a pharmaceutically acceptable salt thereof, with a sigmoidal controlled release profile, into an aqueous solution buffered at pH 7.5 wherein (a) 5% by weight of the drug is released at a time point from 1.5 to 12 hours following addition, (b) 50% by weight of the drug is released at a time point from 5 to 15 hours following addition and (c) 80% by weight of the drug is released at a time point from 6.5 to 20 hours following addition.

21. (Previously Presented) A pharmaceutical formulation comprising the pharmaceutical composition of claim 1 and a pharmaceutically acceptable component which is capable of delivering, at least in part by sigmoidal controlled drug release, a mean plasma concentration of eletriptan, in healthy volunteers, of greater than 10 ng/ml at 20 hours

09/912,774

-4-

PC10915A

post-dosing whilst providing a peak mean plasma concentration of less than 100 ng/ml during the first 10 hours post-dosing.

22. (Original) The pharmaceutical formulation of claim 20 including one or more pharmaceutically acceptable excipient(s), diluent(s) or carrier(s).
23. (Previously Presented) The pharmaceutical formulation of claim 22, said formulation comprising a hard gelatin capsule.
24. (Original) The pharmaceutical formulation of claim 21 including one or more pharmaceutically acceptable excipient(s), diluent(s) or carrier(s).
25. (Previously Presented) The pharmaceutical formulation of claim 24, said formulation comprising a hard gelatin capsule.
26. (Cancelled)
27. (Cancelled)
28. (Cancelled)
29. (Cancelled)
30. (Cancelled)
31. (Cancelled)
32. (Cancelled)
33. (Cancelled)
34. (Cancelled)
35. (Cancelled)
36. (Cancelled)
37. (Cancelled)

09/912,774

-5-

PC10915A

38. (Canceled)

39. (Canceled)

40. (Canceled)

41. (Currently Amended) A process for the preparation of a particulate composition as claimed in claim 1, comprising (a) forming a core ~~containing~~ comprising eletriptan, or a pharmaceutically acceptable salt thereof and (b) coating the core with a water-insoluble, permeable coating comprising one or more acrylic copolymer(s) containing trimethylammoniummethacrylate groups and, optionally, one or more of a plasticiser, an anti-tacking agent or a wetting agent.

42. (Currently Amended) A process for the preparation of a particulate composition, as claimed in claim 1, comprising (a) forming a core by ~~layering~~ dispersing eletriptan, or a pharmaceutically acceptable salt thereof, and, optionally, a pharmaceutically acceptable binder onto the surface of a pharmaceutically acceptable seed and (b) coating the core with a water-insoluble, permeable coating comprising one or more acrylic copolymer(s) containing trimethylammonium-ethylmethacrylate groups; and optionally, one or more of a plasticiser, an anti-tacking agent or a wetting agent.